IDEXX Laboratories Inc Total Assets

Latest as of June 2026: $3.44 Billion USD

IDEXX Laboratories Inc total assets. Based on the latest financial reports, IDEXX Laboratories Inc (IDXX) holds total assets worth $3.44 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see IDEXX Laboratories Inc market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of IDEXX Laboratories Inc (1991–2025)

Total assets of IDEXX Laboratories Inc from 1991 to 2025. This chart illustrates how IDEXX Laboratories Inc's total assets have evolved over time, based on quarterly financial data. See IDEXX Laboratories Inc (IDXX) share price today for real-time trading data and today's change.

IDEXX Laboratories Inc - Asset Composition Analysis

IDEXX Laboratories Inc Total Assets Breakdown (December 2025)

IDEXX Laboratories Inc total assets breakdown as of December 2025. IDEXX Laboratories Inc's total assets of $3.44 Billion consist of 40.0% current assets and 60.0% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 5.4%
Accounts Receivable $693.19 Million 20.7%
Inventory $377.76 Million 11.3%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $109.84 Million 3.3%
Goodwill $414.00 Million 12.4%

Asset Composition Trend (1991–2025)

This chart illustrates how IDEXX Laboratories Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of IDEXX Laboratories Inc to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: IDEXX Laboratories Inc's current assets represent 40.0% of total assets in 2025, a decrease from 69.3% in 1991.
  • Cash Position: Cash and equivalents constituted 5.4% of total assets in 2025, down from 24.4% in 1991.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 1991.
  • Asset Diversification: The largest asset category is accounts receivable at 20.7% of total assets.

IDEXX Laboratories Inc Competitors by Total Assets

Key competitors of IDEXX Laboratories Inc based on total assets are shown below.

Company Country Total Assets
Prostatype Genomics AB
ST:PROGEN
Sweden Skr43.84 Million
Genetic Signatures Ltd
AU:GSS
Australia AU$49.04 Million
Proteome Sciences PLC
LSE:PRM
UK GBX8.26 Million
ProPhase Labs Inc
NASDAQ:PRPH
USA $57.41 Million
Vimian Group AB
ST:VIMIAN
Sweden Skr1.11 Billion
BGI Genomics Co Ltd
SHE:300676
China CN¥11.35 Billion
Clinica Baviera
MC:CBAV
Spain €228.01 Million
Charles River Laboratories
NYSE:CRL
USA $7.53 Billion

IDEXX Laboratories Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.17 1.11 1.48
Quick Ratio 0.87 0.79 1.07
Cash Ratio 0.00 0.00 0.00
Working Capital $221.82 Million $138.48 Million $304.19 Million

IDEXX Laboratories Inc - Advanced Valuation Insights

This section examines the relationship between IDEXX Laboratories Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 25.41
Latest Market Cap to Assets Ratio 12.11
Asset Growth Rate (YoY) 1.7%
Total Assets $3.35 Billion
Market Capitalization $40.58 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values IDEXX Laboratories Inc's assets at a significant premium (12.11x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: IDEXX Laboratories Inc's assets grew by 1.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for IDEXX Laboratories Inc (1991–2025)

The table below shows the annual total assets of IDEXX Laboratories Inc from 1991 to 2025.

Year Total Assets Change
2025-12-31 $3.35 Billion +1.74%
2024-12-31 $3.29 Billion +1.03%
2023-12-31 $3.26 Billion +18.68%
2022-12-31 $2.75 Billion +12.70%
2021-12-31 $2.44 Billion +6.22%
2020-12-31 $2.29 Billion +25.22%
2019-12-31 $1.83 Billion +19.20%
2018-12-31 $1.54 Billion -10.28%
2017-12-31 $1.71 Billion +11.94%
2016-12-31 $1.53 Billion +3.78%
2015-12-31 $1.47 Billion +6.56%
2014-12-31 $1.38 Billion +12.49%
2013-12-31 $1.23 Billion +11.50%
2012-12-31 $1.10 Billion +7.06%
2011-12-31 $1.03 Billion +14.90%
2010-12-31 $897.14 Million +10.96%
2009-12-31 $808.53 Million +5.63%
2008-12-31 $765.44 Million +9.01%
2007-12-31 $702.18 Million +25.49%
2006-12-31 $559.56 Million +14.04%
2005-12-31 $490.68 Million -4.58%
2004-12-31 $514.24 Million -1.46%
2003-12-31 $521.88 Million +25.25%
2002-12-31 $416.65 Million +11.67%
2001-12-31 $373.11 Million +11.11%
2000-12-31 $335.80 Million -6.78%
1999-12-31 $360.20 Million -7.76%
1998-12-31 $390.50 Million +3.58%
1997-12-31 $377.00 Million +0.83%
1996-12-31 $373.90 Million +19.65%
1995-12-31 $312.50 Million +156.78%
1994-12-31 $121.70 Million +24.18%
1993-12-31 $98.00 Million +22.96%
1992-12-31 $79.70 Million +109.19%
1991-12-31 $38.10 Million --

About IDEXX Laboratories Inc

NASDAQ:IDXX USA Diagnostics & Research
Market Cap
$53.26 Billion
Market Cap Rank
#648 Global
#312 in USA
Share Price
$676.04
Change (1 day)
+0.79%
52-Week Range
$504.70 - $766.68
All Time High
$766.68
About

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urin… Read more